Get the Stockscreener App
3.47
0.29%
0.01
After Hours:
3.47
Savara Inc stock is traded at $3.47, with a volume of 630.68K.
It is up +0.29% in the last 24 hours and down -0.29% over the past month.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
See More
Previous Close:
$3.46
Open:
$3.46
24h Volume:
630.68K
Relative Volume:
0.49
Market Cap:
$593.80M
Revenue:
-
Net Income/Loss:
$-54.70M
P/E Ratio:
-12.39
EPS:
-0.28
Net Cash Flow:
$-51.36M
1W Performance:
+10.86%
1M Performance:
-0.29%
6M Performance:
-14.95%
1Y Performance:
-7.71%
1-Day Range:
$3.42
$3.53
1-Week Range:
$3.15
$3.53
52-Week Range:
$2.815
$5.70
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
3.47 | 593.80M | 0 | -54.70M | -51.36M | -0.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-24 | Initiated | JMP Securities | Mkt Outperform |
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
Connor Clark & Lunn Investment Management Ltd. Acquires 242,249 Shares of Savara Inc (NASDAQ:SVRA) - MarketBeat
Savara Grants 150,000 Share Inducement Awards to New Employees | SVRA Stock News - StockTitan
Savara Announces New Employment Inducement Grant - Business Wire
Savara to Present Phase 3 Trial Results for Breakthrough aPAP Treatment at BTS Meeting | SVRA Stock News - StockTitan
Jennison Associates LLC Acquires 1,001,296 Shares of Savara Inc (NASDAQ:SVRA) - MarketBeat
Independent Director of Savara Picks Up 4.5% More Stock - Simply Wall St
Savara Inc. Reports Third-Quarter Financial Results and Announces Key Regulatory Milestones - MSN
Insider Buying Alert: Joseph Mccracken Acquires 20,000 Shares of Savara Inc (SVRA) - GuruFocus.com
Savara director Joseph McCracken acquires $59,071 in common stock - Investing.com India
Savara director Joseph McCracken acquires $59,071 in common stock By Investing.com - Investing.com Canada
Director David Ramsay Acquires 100,000 Shares of Savara Inc (SVR - GuruFocus.com
Savara Inc director David Ramsay buys $287,600 in common stock - Investing.com
Savara Inc director David Ramsay buys $287,600 in common stock By Investing.com - Investing.com UK
Savara (NASDAQ:SVRA) Shares Down 8.5%Time to Sell? - MarketBeat
Prudential Financial Inc's Strategic Acquisition of Savara Inc S - GuruFocus.com
What is HC Wainwright's Estimate for Savara FY2024 Earnings? - MarketBeat
Evercore ISI Reiterates In-Line Rating for Savara (NASDAQ:SVRA) - Defense World
Savara (NASDAQ:SVRA) Reaches New 1-Year Low on Analyst Downgrade - MarketBeat
SVRA stock touches 52-week low at $3.27 amid market challenges - Investing.com India
Savara (NASDAQ:SVRA) Shares Gap Down on Analyst Downgrade - Defense World
500: Something went wrong - Investing.com Canada
Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate - GuruFocus.com
Savara downgraded at Evercore on manufacturing concerns for lung disease candidate - Seeking Alpha
Savara (NASDAQ:SVRA) Price Target Lowered to $6.00 at HC Wainwright - MarketBeat
Savara (NASDAQ:SVRA) Earns "In-Line" Rating from Evercore ISI - MarketBeat
Savara Announces Participation in Upcoming Healthcare Conferences - Business Wire
Jennison Associates LLC's Strategic Acquisition of Savara Inc Sh - GuruFocus.com
Savara Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
Savara Inc (NASDAQ:SVRA) Receives $11.17 Average Price Target from Analysts - MarketBeat
Savara Inc. to Participate in Guggenheim Inaugural Healthcare Conference - MyChesCo
Wellington Management Group LLP's Strategic Acquisition in Savar - GuruFocus.com
SVRASavara Inc. Latest Stock News & Market Updates - StockTitan
Savara (NASDAQ:SVRA) Stock Price Down 5.1%Should You Sell? - MarketBeat
Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference - StockTitan
Savara Inc. Shines Spotlight on Rare Lung Disease in New TV Feature - MSN
Savara Inc. Rewards New Employees with Inducement Awards - MSN
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV - Business Wire
Savara Inc (NASDAQ:SVRA) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Savara Announces New Employment Inducement Grant | SVRA Stock News - StockTitan
Savara Inc (SVRA) deserves deeper analysis - US Post News
Ratio Review: Analyzing Savara Inc (SVRA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Savara Inc (SVRA) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
Savara Inc. Launches Early Access Program for Rare Lung Disease Treatment - MSN
Savara maintains Overweight rating from Piper Sandler on bullish aPAP therapy prospects - Investing.com UK
Savara (NASDAQ:SVRA) Trading Down 3.4%Here's What Happened - MarketBeat
Cantaloupe, Inc. Executives Boost Confidence with Significant Stock Purchases - MyChesCo
Savara stock outlook steady as H.C. Wainwright highlights challenges in doctor engagement at CHEST meeting - Investing.com
Savara (NASDAQ:SVRA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Should investors be concerned about Savara Inc (SVRA)? - US Post News
The growth track for Savara Inc (SVRA) has changed recently - SETE News
Stock Surge: Savara Inc (SVRA) Closes at 3.82, Marking a 0.26 Increase/Decrease - The Dwinnex
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Savara Inc Stock (SVRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RAMSAY DAVID A | Director |
Nov 18 '24 |
Buy |
2.88 |
100,000 |
287,600 |
2,323,642 |
| Pauls Matthew | CHIEF EXECUTIVE OFFICER |
Dec 28 '23 |
Sale |
4.71 |
84,000 |
395,900 |
1,302,674 |
| Lowrance David L | CHIEF FINANCIAL OFFICER |
Dec 28 '23 |
Sale |
4.71 |
10,000 |
47,131 |
342,355 |
| Elam Nevan C | Director |
Dec 28 '23 |
Option Exercise |
1.30 |
53,758 |
69,722 |
116,343 |
| Elam Nevan C | Director |
Dec 28 '23 |
Sale |
4.71 |
93,843 |
442,291 |
22,500 |
| Hawkins Richard J | Director |
Dec 11 '23 |
Option Exercise |
0.82 |
10,841 |
8,890 |
12,741 |
| Elam Nevan C | Director |
Dec 11 '23 |
Option Exercise |
0.82 |
10,841 |
8,890 |
40,085 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):